Market overview
The global comparator sourcing market is worth USD 976 mn in 2026 and is forecast to reach USD 2.2 bn by 2036, growing at a 8.5% CAGR. United States is the largest country market and Oncology is the largest by therapeutic area segment.
| Scope | Sourcing of marketed reference medicines used as comparators in clinical trials, with purchase, relabelling, certification and delivery to study sites, sold to drug developers. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 900 mn |
| Value 2026 | USD 976 mn |
| Value 2036 | USD 2.2 bn |
| CAGR 2026-2036 | 8.5% |
| Volume 2026 | 31.9 thousand projects |
| Volume 2036 | 59.2 thousand projects |
| Average price 2026 | USD 30,600 per project |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Comparator Sourcing market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 976.5 mn |
| 2027 | USD 1.06 bn |
| 2028 | USD 1.15 bn |
| 2029 | USD 1.25 bn |
| 2030 | USD 1.35 bn |
| 2031 | USD 1.47 bn |
| 2032 | USD 1.59 bn |
| 2033 | USD 1.73 bn |
| 2034 | USD 1.88 bn |
| 2035 | USD 2.03 bn |
| 2036 | USD 2.21 bn |
Comparator Sourcing market segmentation
By therapeutic area
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Oncology | 34.0% | 38.5% | USD 332 mn | 9.8% |
| Immunology | 18.0% | 18.6% | USD 176 mn | 8.8% |
| Cardiovascular and metabolic | 18.0% | 15.4% | USD 176 mn | 6.8% |
| Neurology | 14.0% | 13.8% | USD 137 mn | 8.3% |
| Others | 16.0% | 13.7% | USD 156 mn | 6.8% |
By phase
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Phase II | 24.0% | 24.2% | USD 234 mn | 8.6% |
| Phase III | 60.0% | 60.4% | USD 586 mn | 8.6% |
| Phase IV | 16.0% | 15.4% | USD 156 mn | 8.1% |
By source region
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| United States sourced | 38.0% | 36.0% | USD 371 mn | 7.9% |
| European sourced | 34.0% | 33.0% | USD 332 mn | 8.2% |
| Asia sourced | 16.0% | 18.0% | USD 156 mn | 9.8% |
| Others regions | 12.0% | 13.0% | USD 117 mn | 9.4% |
By drug form
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Oral solids | 36.0% | 33.0% | USD 352 mn | 7.6% |
| Injectables | 38.0% | 38.0% | USD 371 mn | 8.5% |
| Biologics | 26.0% | 29.0% | USD 254 mn | 9.7% |
By client
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Large pharma | 48.0% | 44.0% | USD 469 mn | 7.6% |
| Biotech | 30.0% | 34.0% | USD 293 mn | 9.9% |
| CROs | 22.0% | 22.0% | USD 215 mn | 8.5% |
Top 25 countries for comparator sourcing by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 86.0% of 2026 revenue and the 25 countries below together hold 97.2%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 371 mn | 38.0% | USD 799 mn | 8.0% |
| 2 | Germany | USD 78 mn | 8.0% | USD 177 mn | 8.5% |
| 3 | United Kingdom | USD 78 mn | 8.0% | USD 177 mn | 8.5% |
| 4 | China | USD 78 mn | 8.0% | USD 243 mn | 12.0% |
| 5 | France | USD 49 mn | 5.0% | USD 106 mn | 8.1% |
| 6 | Japan | USD 49 mn | 5.0% | USD 102 mn | 7.6% |
| 7 | Canada | USD 39 mn | 4.0% | USD 84 mn | 7.9% |
| 8 | Switzerland | USD 39 mn | 4.0% | USD 84 mn | 7.9% |
| 9 | Spain | USD 29 mn | 3.0% | USD 66 mn | 8.5% |
| 10 | Italy | USD 29 mn | 3.0% | USD 64 mn | 8.1% |
| 11 | Netherlands | USD 16 mn | 1.6% | USD 34 mn | 8.1% |
| 12 | Belgium | USD 14 mn | 1.4% | USD 30 mn | 8.1% |
| 13 | India | USD 14 mn | 1.4% | USD 33 mn | 9.4% |
| 14 | Australia | USD 11 mn | 1.1% | USD 24 mn | 8.1% |
| 15 | Sweden | USD 8.8 mn | 0.9% | USD 19 mn | 8.1% |
| 16 | Denmark | USD 8.6 mn | 0.9% | USD 19 mn | 8.1% |
| 17 | South Korea | USD 6.9 mn | 0.7% | USD 17 mn | 9.4% |
| 18 | Brazil | USD 5.6 mn | 0.6% | USD 14 mn | 9.4% |
| 19 | Israel | USD 5.5 mn | 0.6% | USD 12 mn | 8.1% |
| 20 | Mexico | USD 4.4 mn | 0.5% | USD 11 mn | 9.4% |
| 21 | Poland | USD 4.1 mn | 0.4% | USD 10 mn | 9.5% |
| 22 | Austria | USD 3.3 mn | 0.3% | USD 7.1 mn | 7.8% |
| 23 | Singapore | USD 3.0 mn | 0.3% | USD 7.5 mn | 9.5% |
| 24 | Turkey | USD 2.8 mn | 0.3% | USD 6.8 mn | 9.2% |
| 25 | Saudi Arabia | USD 2.0 mn | 0.2% | USD 5.1 mn | 9.5% |
| Rest of world | USD 28 mn | 2.8% | USD 57 mn | 7.6% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Clinigen
- Thermo Fisher Scientific
- Almac Group
Group 2: Regional and specialist players
- Myonex
- Tanner Pharma Group
- Ancillare
- Mawdsleys Clinical Supplies
- Catalent
- PCI Pharma Services
- Sharp Services
- KLIFO
Group 3: Emerging and niche players
- Yourway
- Bionical Emas
- Bilcare Global Clinical Supplies
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the comparator sourcing market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 8.5% is calculated from the resulting values.
The market is divided by therapeutic area, by phase, by source region, by drug form, by client. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the comparator sourcing market?
The global comparator sourcing market is estimated at USD 900 mn in 2025 and USD 976 mn in 2026.
How fast will the comparator sourcing market grow?
It is forecast to reach USD 2.2 bn by 2036, a compound annual growth rate of 8.5% from 2026, an increase of USD 1.2 bn.
Which country is the largest market for comparator sourcing?
United States is the largest market by revenue at USD 371 mn in 2026, 38.0% of the global total. The three largest countries together hold 54.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 12.0% a year from 2026 to 2036.
Which comparator sourcing segment is largest?
In the by therapeutic area split, Oncology is the largest segment with 34.0% of 2026 revenue.
Who are the leading comparator sourcing companies?
Global leaders include Clinigen, Thermo Fisher Scientific, Almac Group.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Endoluminal & Bronchoscopy RobotsUSD 976 mn · 17.0% CAGR
- Digital Twins TechnologiesUSD 967 mn · 21.0% CAGR
- Oncology Biomarker Translation ServicesUSD 990 mn · 9.5% CAGR
- Biosafety CabinetUSD 958 mn · 7.0% CAGR
- Endoscopic Imaging Logistics And ServiceUSD 1.0 bn · 5.5% CAGR
- Hospital Capacity Management SolutionsUSD 1.0 bn · 11.0% CAGR
- Glioblastoma Treatment DrugsUSD 945 mn · 5.5% CAGR
- Robotic Catheterization SystemsUSD 944 mn · 15.0% CAGR